Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs.
Generic drugs represent a significant portion of the medical arsenal in treating disease. As copies of originator drugs, these drugs have been permitted abbreviated approval under the Hatch-Waxman Act. Yet with the current cost focus upon generic formulations, potential safety issues with generics have arisen. Although there is an established criterion of "bioequivalence" that generic formulations must demonstrate, narrow-therapeutic index drugs for sensitive clinical circumstances such as epilepsy, antiplatelet therapies, and mental health treatments may require different regulatory treatment than other generic drugs. Further, in these circumstances, differences in generic formulations may lead to adverse clinical outcomes due to less stringent bioequivalence tolerances. Yet there is no mandate for comparison between different generic formulations. Countries outside the United States advocate for narrowing tolerance ranges for these high risk health situations and the drugs for their treatment. We argue in this paper that additional patient safety matters must be taken into account for narrow therapeutic disease drugs, and regulatory bodies should emphasize greater tightness in bioequivalence before these narrow-therapeutic drug generic formulations are approved.
Institute of Health Law Studies, California Western School of Law, USA.
Michelle
M
Hottinger
Bryan A
BA
Liang
D000925:Anticoagulants / Q000493:pharmacokinetics; D000927:Anticonvulsants / Q000493:pharmacokinetics; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics; D016642:Bupropion / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000493:pharmacokinetics*; D006801:Humans; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000493:pharmacokinetics
D000925:Anticoagulants; D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D016568:Drugs, Generic; D016642:Bupropion; D014859:Warfarin